ArticleBritish journal of cancer2019
Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.
Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Urinary and cellular volatile organic compounds as biomarkers for urological cancers: a systematic review of GC-MS-based volatolomics.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- Exploring Components, Sensors, and Techniques for Cancer Detection via eNose Technology: A Systematic Review.Sensors (Basel, Switzerland) · 2024Pooled it
- The diagnostic value of miRNA-141 in prostate cancer: A systematic review and PRISMA-compliant meta-analysis.Medicine · 2020Pooled it
- Identification of potential salivary biomarker panels for oral squamous cell carcinoma.Scientific reports · 2021Trial
- Machine Learning-Based Profiling of Urinary Volatile Organic Compounds Reveals Distinct Diagnostic Signatures for Gastric Cancer.Cancer medicine · 2026Article
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- Oncometabolite signatures from tumor-stroma crosstalk as potential non-invasive biomarkers.Cell death discovery · 2026Article
- Characterization of Volatile Organic Compounds Released byMetabolites · 2026Article
- The Volatilomes ofMycobiology · 2026Review
- Influence of pre-analytical factors and biological variability on the urinary volatilome.Analytical and bioanalytical chemistry · 2025Article
- Article
- Evaluation of salivary and serum Exosomal mRNAs as biomarkers for the diagnosis and prognosis of oral squamous cell carcinoma.Scientific reports · 2025Article
- Identification of volatile organic compound as a novel modality for cervical cancer detection.Obstetrics & gynecology science · 2025Article
- Steps toward clinical validation of exhaled volatile organic compound biomarkers for hypoglycemia in persons with type 1 diabetes.Scientific reports · 2025Article
- Predicting Clinically Significant Prostate Cancer Using Urine Metabolomics via Liquid Chromatography Mass Spectrometry.The world journal of men's health · 2025Article
- A Comprehensive Review of Biomarker Sensors for a Breathalyzer Platform.Sensors (Basel, Switzerland) · 2024Review
- The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review.BJUI compass · 2024Review
- Identifying potential breath biomarkers for early diagnosis of papillary thyroid cancer based on solid-phase microextraction gas chromatography-high resolution mass spectrometry with metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Potential urinary volatile organic compounds as screening markers in cancer - a review.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lack of sensitive and specific biomarkers for the early detection of prostate cancer (PCa) is a major hurdle to improve patient management.
methodsA metabolomics approach based on GC-MS was used to investigate the performance of volatile organic compounds (VOCs) in general and, more specifically, volatile carbonyl compounds (VCCs) present in urine as potential markers for PCa detection.
resultsResults showed that PCa patients (n = 40) can be differentiated from cancer-free subjects (n = 42) based on their urinary volatile profile in both VOCs and VCCs models, unveiling significant differences in the levels of several metabolites. The models constructed were further validated using an external validation set (n = 18 PCa and n = 18 controls) to evaluate sensitivity, specificity and accuracy of the urinary volatile profile to discriminate PCa from controls. The VOCs model disclosed 78% sensitivity, 94% specificity and 86% accuracy, whereas the VCCs model achieved the same sensitivity, a specificity of 100% and an accuracy of 89%. Our findings unveil a panel of 6 volatile compounds significantly altered in PCa patients' urine samples that was able to identify PCa, with a sensitivity of 89%, specificity of 83%, and accuracy of 86%.
conclusionsIt is disclosed a biomarker panel with potential to be used as a non-invasive diagnostic tool for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.